On Tuesday, the direct-to-consumer health-care startup Ro introduced a new, complimentary tool designed to help patients determine whether their insurance covers GLP-1 medications, a popular class of drugs used for weight loss and diabetes management.
GLP-1 medications, such as Novo Nordisk’s Wegovy for weight loss and Ozempic for diabetes, often have their costs covered by insurance when used for diabetes treatment. However, coverage for weight loss purposes is less common, and navigating the insurance landscape can be challenging for patients and time-consuming for prescribing doctors. Ro’s tool aims to simplify this process by providing patients with detailed information about their insurance coverage for these medications.
According to Ro’s customer data, nearly 50% of its patients have some form of insurance coverage for GLP-1 drugs. The company’s new tool is designed to help patients better understand their coverage options, potentially guiding them in their weight loss journey and encouraging participation in Ro’s GLP-1 program. The tool may also help Ro attract more patients by clarifying coverage details.
Demand for GLP-1 medications has surged, with drug shortages reported over the past year. The market for these drugs is projected to exceed $100 billion by the end of the decade, prompting digital health companies like Ro to innovate and capture market share.
Ro’s program not only facilitates prescriptions for GLP-1 drugs but also offers compounded versions when branded ones are unavailable. The program includes monthly consultations with doctors, 24/7 messaging, one-on-one coaching, and support with insurance navigation.
Patients can access Ro’s insurance checker online by entering basic medical and insurance details. Within one to three days, they receive a personalized report detailing their insurance coverage, any required prior authorizations, estimated copays, and next steps. The report also addresses potential out-of-pocket costs and medication supply issues.
Ro co-founder and CEO Zachariah Reitano emphasized the importance of providing early and comprehensive information to patients. “Understanding coverage and costs at the outset can significantly influence the treatment journey,” he said. The new tool aims to be the first step for individuals considering GLP-1 treatments, regardless of whether they choose Ro or another healthcare provider.
Read More: Click Here
